CL2018002874A1 - Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). - Google Patents

Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).

Info

Publication number
CL2018002874A1
CL2018002874A1 CL2018002874A CL2018002874A CL2018002874A1 CL 2018002874 A1 CL2018002874 A1 CL 2018002874A1 CL 2018002874 A CL2018002874 A CL 2018002874A CL 2018002874 A CL2018002874 A CL 2018002874A CL 2018002874 A1 CL2018002874 A1 CL 2018002874A1
Authority
CL
Chile
Prior art keywords
methods
virus
antibodies against
divisional application
against influenza
Prior art date
Application number
CL2018002874A
Other languages
English (en)
Inventor
Min Xu
Ning Chai
Nancy Chiang
Henry Chiu
Zhonghua Lin
Gerald R Nakamura
Hyunjoo Park
Lee Swem
Mercedes Balazs
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2018002874A1 publication Critical patent/CL2018002874A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS DE HEMAG)UTININA CONTRA EL VIRUS DE LA INFLUENZA B. COMPOSICIONES QUE COMPRENDEN ANTICUERPOS DE HEMAGLUTININA CONTRA E) VIRUS DE LA INFLUENZA B Y SUS MÉTODOS DE USO.
CL2018002874A 2014-03-27 2018-10-09 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). CL2018002874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461971123P 2014-03-27 2014-03-27

Publications (1)

Publication Number Publication Date
CL2018002874A1 true CL2018002874A1 (es) 2018-12-14

Family

ID=52829396

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016002413A CL2016002413A1 (es) 2014-03-27 2016-09-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CL2018002874A CL2018002874A1 (es) 2014-03-27 2018-10-09 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016002413A CL2016002413A1 (es) 2014-03-27 2016-09-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso

Country Status (20)

Country Link
US (2) US9745365B2 (es)
EP (1) EP3122771A1 (es)
JP (1) JP2017512471A (es)
KR (1) KR20160135830A (es)
CN (1) CN106132987A (es)
AR (1) AR099855A1 (es)
AU (1) AU2015235983A1 (es)
BR (1) BR112016022113A2 (es)
CA (1) CA2942820A1 (es)
CL (2) CL2016002413A1 (es)
CR (1) CR20160502A (es)
EA (1) EA201691945A1 (es)
IL (1) IL247870A0 (es)
MA (1) MA39803A (es)
MX (1) MX2016012530A (es)
PE (1) PE20161376A1 (es)
PH (1) PH12016501873A1 (es)
SG (1) SG11201607945UA (es)
TW (1) TW201620932A (es)
WO (1) WO2015148806A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190005966A (ko) 2016-05-10 2019-01-16 제넨테크, 인크. 폴리펩타이드의 재조합 생산 동안 트리설파이드 결합을 감소시키기 위한 방법
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
CN113631711B (zh) 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
MY207220A (en) * 2019-10-28 2025-02-06 Regeneron Pharma Anti-hemagglutinin antibodies and methods of use thereof
BR112022014278A2 (pt) * 2020-01-24 2022-09-20 Regeneron Pharma Conjugados de composto proteico-antiviral
JP2023518841A (ja) 2020-03-26 2023-05-08 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質が減少した修飾哺乳動物細胞
EP4172346A1 (en) 2020-06-24 2023-05-03 Genentech, Inc. Targeted integration of nucleic acids
WO2021262783A1 (en) 2020-06-24 2021-12-30 Genentech, Inc. Apoptosis resistant cell lines
CA3192344A1 (en) 2020-08-28 2022-03-03 Genentech, Inc. Crispr/cas9 multiplex knockout of host cell proteins
CN114316032B (zh) * 2020-09-27 2022-12-27 东莞市朋志生物科技有限公司 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒
JP2024514222A (ja) 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
KR20250107893A (ko) 2022-11-15 2025-07-14 제넨테크, 인크. 숙주 세포로의 트랜스포존 매개 통합 및 핵산의 표적 통합의 조합
US20240240175A1 (en) 2023-01-12 2024-07-18 Genentech, Inc. Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US20250011420A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Proteins that bind sp17 including fully-human anti-sp17 antibodies
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BE1018561A3 (fr) 2008-12-24 2011-03-01 Galactic Sa Procede de purification de l'acide lactique par cristallisation.
US8975378B2 (en) 2008-12-25 2015-03-10 Osaka University Human anti-human influenza virus antibody
IN2014CN00953A (es) 2011-07-14 2015-04-10 Crucell Holland Bv
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
EP2822968B1 (en) 2012-03-08 2018-01-10 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Also Published As

Publication number Publication date
CL2016002413A1 (es) 2017-06-23
SG11201607945UA (en) 2016-10-28
CA2942820A1 (en) 2015-10-01
US20150274812A1 (en) 2015-10-01
AR099855A1 (es) 2016-08-24
JP2017512471A (ja) 2017-05-25
IL247870A0 (en) 2016-11-30
AU2015235983A1 (en) 2016-10-06
US20170320937A1 (en) 2017-11-09
CN106132987A (zh) 2016-11-16
PE20161376A1 (es) 2016-12-26
PH12016501873A1 (en) 2017-01-09
EA201691945A1 (ru) 2017-02-28
US9745365B2 (en) 2017-08-29
EP3122771A1 (en) 2017-02-01
KR20160135830A (ko) 2016-11-28
MX2016012530A (es) 2017-01-05
BR112016022113A2 (pt) 2017-10-31
CR20160502A (es) 2017-02-03
MA39803A (fr) 2017-02-01
TW201620932A (zh) 2016-06-16
WO2015148806A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
MX387661B (es) Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
UY36221A (es) Derivados de isoindolinona
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.